Theriva Biologics, Inc.

Listed Company

TOVXCIK 0000894158NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-23.70M

Total Assets

$38.24M

Equity

$15.38M

Shares Out

45.89M

Op. Cash Flow

$-16.67M

TOVX$0.23−51.82% · past yearDBEQ Basic

Daily closing prices

Business

Theriva Biologics is a clinical-stage biopharmaceutical company developing oncology and gastrointestinal therapeutics. The company's lead product candidate, VCN-01 (zabilugene almadenorepvec), is a genetically modified oncolytic adenovirus in Phase 2b development for pancreatic cancer and Phase 1 development for retinoblastoma and other solid tumors. Earlier-stage programs include SYN-004 (ribaxamase) for prevention of antibiotic-associated microbiome damage, which Theriva is exploring for out-licensing, and SYN-020 (oral intestinal alkaline phosphatase), which was licensed exclusively to Rasayana Therapeutics in February 2026.

Summary from 10-K filed 2026-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
General and administrative	15	7	7	10	6
Research and development	9	12	14	12	8
In-process research and development impairment	0	1	0	—	—
Goodwill impairment	—	6	0	—	—
Total Operating Costs and Expenses	24	26	21	22	14
Loss from Operations	−24	−26	−21	−22	−14
Foreign currency exchange gain (loss)	25,000	−4,000	3,000	−41,000	0
Interest income	287,000	697,000	1	512,000	6,000
Total Other Income	312,000	693,000	1	471,000	6,000
Net Loss before income taxes	−24	−26	−20	−21	−14
Income tax benefit	—	—	2	1	0
Net Loss	−24	−26	−18	−20	−14
Less deemed dividend from warrant inducement	−2	—	—	—	—
Net Loss Attributable to Common Stockholders	−25	−26	−18	−20	−23
Net Loss Per Share - Basic (in dollars per share)	−2.08	−19.03	−28.48	−1.31	−1.9
Net Loss Per Share - Dilutive (in dollars per share)	−2.08	−19.03	−28.48	−1.31	−1.9
Weighted average number of shares outstanding during the period - Basic (in shares)	12	1	644,282	15	12
Weighted average number of shares outstanding during the period - Dilutive (in shares)	12	1	644,282	15	12
Gain (loss) on foreign currency translation	2	−1	711,000	−679,000	0
Total comprehensive loss	−22	−27	−18	−20	−14

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-09-30
Cash and cash equivalents	13	12	23	42	50
Tax credit receivable	3	3	2	—	—
Prepaid expenses and other current assets	1	1	2	4	2
Total Current Assets	17	16	27	46	53
Property and equipment, net	222,000	270,000	422,000	345,000	262,000
Restricted cash	46,000	96,000	102,000	99,000	90,000
Right of use asset	803,000	1	2	1	1
In-process research and development	20	17	20	19	18
Deposits and other assets	82,000	75,000	78,000	23,000	23,000
Total Assets	38	35	55	72	77
Accounts payable	1	859,000	770,000	915,000	770,000
Accrued expenses	6	3	3	1	1
Accrued employee benefits	443,000	1	2	1	1
Deferred research and development tax credit-current portion	2	2	906,000	—	—
Loans payable-current	57,000	61,000	63,000	57,000	52,000
Operating lease liability-current portion	549,000	539,000	487,000	216,000	157,000
Total Current Liabilities	10	8	7	7	12
Non-current contingent consideration	10	7	6	7	2
Loan Payable - non-current	2	92,000	162,000	221,000	202,000
Non-current deferred research and development tax credit	815,000	762,000	906,000	—	—
Non-current operating lease liability	352,000	873,000	1	1	1
Total Liabilities	23	16	16	17	18
Commitments and Contingencies (Note 12)	—	—	—	—	—
Common stock, $0.001 par value; 350,000,000 shares authorized, 35,717,159 issued and 35,688,350 outstanding at December 31, 2025 and 2,811,259 issued and 2,782,449 outstanding at December 31, 2024	34,000	3,000	1,000	16,000	16,000
Additional paid-in capital	374	356	347	344	344
Treasury stock at cost, 28,809 shares at December 31, 2025 and at December 31, 2024	−288,000	−288,000	−288,000	−288,000	—
Accumulated other comprehensive income (loss)	755,000	−1	32,000	−679,000	−3
Accumulated deficit	−359	−335	−309	−291	−285
Total Stockholders' Equity	15	19	37	52	56
Total Liabilities and Stockholders' Equity	38	35	55	72	77

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	654,000	671,000	552,000	475,000	416,000
Change in fair value of contingent consideration	9	699,000	−660,000	2	0
Loss on asset disposal	1,000	—	—	—	—
Non - cash lease expense	522,000	452,000	388,000	183,000	—
Depreciation	108,000	137,000	135,000	85,000	87,000
Deferred research and development tax credit	−188,000	−888,000	0	—	—
Prepaid expenses and other current assets	456,000	912,000	1	−363,000	174,000
Deposits and other assets	—	1,000	−54,000	0	—
Accounts payable	69,000	123,000	−157,000	−385,000	−363,000
Accrued expenses	−2	522,000	1	−267,000	1
Accrued employee benefits	−744,000	−350,000	104,000	333,000	110,000
Operating lease liability	−562,000	−482,000	−422,000	−124,000	−216,000
Net Cash Used In Operating Activities	−17	−17	−19	−19	−13
Purchases of property and equipment	−35,000	−1,000	−202,000	−116,000	−14,000
Net Cash Used In Investing Activities	−35,000	−1,000	−202,000	−4	−14,000
Payment of loans payable	−70,000	−67,000	—	—	—
Proceeds from issuance under at - the - market offering, net of issuance cost	7	4	2	0	—
Payment of contingent consideration	−1	—	—	—	—
Proceeds from issuance Common Stock and Warrants offering, net of issuance costs	7	2	0	—	—
Proceeds from warrant inducement	4	—	—	—	—
Proceeds from long term debt	2	—	—	—	—
Proceeds from issuance of common stock for warrant exercises	4,000	—	—	0	8
Tax credit receivable	287,000	—	—	—	—
Net Cash Provided By Financing Activities	18	5	625,000	−2	74
Effects of exchange rate changes on cash and cash equivalents	−92,000	−132,000	−33,000	−32,000	0
Net increase (decrease) in cash and cash equivalents and restricted cash	1	−12	−19	−25	61
Noncash equity issuance costs and deemed dividend	6	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Theriva Biologics, Inc.'s CIK number?

Theriva Biologics, Inc.'s SEC CIK number is 0000894158 (894158). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Theriva Biologics, Inc.'s SEC filings?

All of Theriva Biologics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Theriva Biologics, Inc. last report earnings?

Theriva Biologics, Inc. (TOVX) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-055679). This is Theriva Biologics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Theriva Biologics, Inc.'s most recent earnings 8-K?

Theriva Biologics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001104659-26-055679. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Theriva Biologics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →